Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01459913 · ClinicalTrials.gov registry record · Phase 3
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 239
- Enrollment target
NCT01459913 is a Phase 3 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 239 participants.
The verdict
NCT01459913, a Phase 3 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 239 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV) infection and will not have cirrhosis of the liver.
Interventions
- DRUG Ribavirin
- DRUG Telaprevir
- DRUG Pegylated Interferon Alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01459913
The ClinicalTrials.gov registry entry for NCT01459913 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01459913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01459913 about?
NCT01459913 is a clinical study titled "Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype". The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study ...
What is the current status of trial NCT01459913?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 239 participants. The study started on 2011-11. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01459913?
The interventions under investigation include: Ribavirin (DRUG), Telaprevir (DRUG), Pegylated Interferon Alfa-2a (DRUG).
Who is sponsoring clinical trial NCT01459913?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.